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The Wnt signaling pathway was initially discovered for its role in tumorigenesis and the development of Drosophila
and other eukaryotic organisms. The key effector of this pathway, the bipartite transcription factor β-cat/TCF, is
formed by free β-catenin (β-cat) and a TCF protein, including TCF7L2. Extensive recent investigations have
highlighted the role of the Wnt signaling pathway in metabolic homeostasis and its implication in diabetes and
other metabolic diseases. Genome-wide association studies have shown that several key components of the Wnt
signaling pathway are implicated in metabolic homeostasis and the development of type 2 diabetes (T2D). Despite
controversial observations regarding the role of Wnt signaling in the development and function of pancreatic islets,
the discovery of the association between certain single nucleotide polymorphisms of TCF7L2 and T2D susceptibility
has fueled great efforts to explore the role of Wnt signaling in the function of pancreatic β-cells and glucose
homeostasis. Here we have introduced our basic understanding of the canonical Wnt signaling pathway,
summarized our current knowledge on its implication in metabolic homeostasis and T2D, discussed the work on
TCF7L2 as a T2D susceptibility gene, and presented the controversial role of Wnt signaling and TCF7L2 in
pancreatic islets as well as their potential metabolic function in other organs. We then expanded our view into the
crosstalk among Wnt, insulin and FOXO signaling cascades, which further illustrates the complexity of the Wnt
signaling pathway in metabolic homeostasis. Finally, we have presented our perspectives.
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The Wnt signaling pathway was initially recognized in
breast and colon cancer research as well as in embryonic
developmental studies of Drosophila, Xenopus and other
organisms [1-3]. This pathway involves not only a large
battery of Wnt ligands, receptors and co-receptors, but
also a number of proteins that can regulate the produc-
tion of the Wnt ligands, the interactions between differ-
ent types of Wnt ligands and receptors on the target
cells, the physiological responses of target cells to Wnt
ligand binding, as well as the formation of active effector
molecules. Hyper-activation of the Wnt signaling path-
way, such as via the attenuation of the repressive ma-
chinery or the expression of a constitutively active* Correspondence: tianru.jin@utoronto.ca
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reproduction in any medium, provided the oreffector, may lead to the development of colorectal and
other types of tumors [4]. During the last decade, we
have learned that Wnt signaling not only interacts with
several other important signaling pathways in orchestrat-
ing organogenesis, but is also involved in regulating hor-
mone gene expression and metabolic homeostasis [5,6].
Abnormalities in the Wnt signaling pathway may lead to
the development of diseases other than tumors, includ-
ing type 2 diabetes (T2D) and other disorders [7-11].
The major effector of the canonical Wnt signaling
pathway (defined as Wnt pathway hereafter) is known as
β-cat/TCF. This bipartite transcription factor is formed
by free β-catenin (β-cat) and a member of the TCF pro-
tein family, including TCF7L2, which was previously
known as TCF-4 [12]. In 2006, a large scale genome-
wide association study (GWAS) revealed that certain
single nucleotide polymorphisms (SNPs) in TCF7L2 are
strongly associated with the susceptibility of T2D [13].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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merous times globally in different ethnic groups in the
last few years [14-23]. Although we are still unable to
determine mechanistically how these SNPs located
within intronic regions of TCF7L2 affect the risk of
T2D, this association, along with the recognition of the
role of the Wnt signaling in the production and function
of incretin hormones and blood glucose homeostasis,
has prompted us to further investigate the function of
the Wnt signaling pathway in the patho-physiology of
T2D and other metabolic disorders [24].
Genetic variations of several other components of the
Wnt signaling pathway were also shown to be involved
in the susceptibility of diabetes or glucose homeostasis.
In addition, Wnt signaling pathway deficiency was found
to cause osteoporosis [25,26]. This is due to the exist-
ence of crosstalk between the developmental Wnt sig-
naling pathway and the aging related FOXO/stress
signaling pathway [26,27]. In this review, we have intro-
duced the basic concept of the Wnt signaling pathway,
summarized the current studies on the role of the Wnt
signaling pathway in metabolic homeostasis and the de-
velopment of metabolic diseases, presented current dis-
putes on the function of Wnt signaling in pancreatic
islet β-cells, and discussed the extensive recent work on
TCF7L2 as a diabetes susceptibility gene. We have then
further expanded our view into the crosstalk among the
Wnt, insulin and FOXO signaling cascades, which
allowed us to appreciate the complexity of the Wnt sig-
naling pathway and to present our perspectives.
Introduction of the wnt signaling pathway
In 1982, Nusse and Varmus discovered the first Wnt
ligand-encoding gene, Int-1, in their breast cancer re-
search [3]. This proto-oncogene was later renamed Wnt-
1, since it shares strong amino acid sequence homology
with the Drosophila Wingless (wg), which is important
for segment polarity of the insect [28]. Today, there are
19 Wnt genes identified in rodents and humans. Wnt
ligands are secreted glycoproteins which mainly exert
their functions via the selective interaction with more
than a dozen seven-transmembrane domain Frizzled
receptors as well as the co-receptor known as low-
density lipoprotein receptor-related protein 5 or 6
(LRP5/6).
The key effector of the Wnt signaling pathway is the
bipartite transcription factor β-cat/TCF, formed by free
β-cat and a member of the TCF family [TCF-1/TCF7,
LEF-1, TCF-3/TCF7L1 and TCF-4/TCF7L2]. Free β-cat
concentration in the cytosol of resting cells is tightly
controlled by the proteasome-mediated degradation
process through the actions of adenomatous polyposis
coli (APC), axin/conductin, and the serine/threonine
kinases glycogen synthase kinase-3 (GSK-3) and caseinkinase Iα (CK-1α, Figure 1A) [29,30]. APC and axin
serve as the scaffold, while GSK-3 and CK-1α phosphor-
ylate certain serine (Ser) residues at the N-terminus of
β-cat, including the Ser33 position. Once β-cat is phos-
phorylated at the N-terminal positions, it is ubiquiti-
nated and degraded by the proteasome. Following
binding of a Wnt ligand to the Frizzled receptor and
LRP5/6 co-receptor, an association is made between the
Wnt receptors and Dishevelled (Dvl), an event that
triggers the disruption of the complex that contains
APC, axin, GSK-3, and β-cat, thus preventing the
phosphorylation-dependent degradation of β-cat. This
leads to the translocation of β-cat into the nucleus, the
formation of the β-cat/TCF complex, and the activation
of β-cat/TCF (or Wnt) downstream target genes
(Figure 1B).
GSK-3 has been recognized as an important negative
modulator of the Wnt signaling pathway [31]. Lithium
and other inhibitors of GSK-3 can mimic the function of
Wnt ligands in stimulating the expression of Wnt down-
stream target genes (Figure 1B) [31]. Furthermore, the
Wnt effector β-cat/TCF may also function as an effector
for other signaling cascades, including insulin, insulin-
like growth factor-1 (IGF-1), glucagon-like peptide-1
(GLP-1) and a number of other peptide hormones and
neurotransmitters that use cAMP as a second messenger
[27]. In a number of cell lineages, activation of protein
kinase A (PKA) was shown to stimulate β-cat phosphor-
ylation at Ser675, an event that is positively associated
with the activation of β-cat/TCF-mediated Wnt target
gene expression [32].
Genetic studies revealing the involvement of wnt
pathway components in the susceptibility of
diabetes and obesity
Investigations have shown that several Wnt pathway
components are important for normal lipid and
glucose metabolism and hence the pathophysiology
of metabolic disorders. LRP-5 and LRP-6 are co-
receptors for the Wnt ligands [33,34] (Figure 1).
The human LRP-5 gene is mapped within the
IDDM4 region, which is linked to type 1 diabetes
(T1D) on chromosome 11q13 [35-37]. A GWAS by
Guo and colleagues revealed that polymorphisms of
LRP-5 are strongly associated with obesity pheno-
types as well [38]. The homozygous LRP-5 knockout
(LRP-5−/−) mice showed increased plasma cholesterol
levels after a high-fat diet (HFD) challenge [39]. In
addition, when the LRP-5−/− mice were fed with a
normal diet, they also showed markedly impaired
glucose tolerance [39]. Furthermore, LRP-5−/− mice
had a significant reduction in the levels of intracel-
lular ATP and calcium in response to high glucose
treatment, along with decreased glucose-induced
Figure 1 Schematic of the canonical Wnt signaling pathway. A) In the absence of Wnt ligands, β-cat is sequestered in the cytoplasm by the
destruction complex consisting of APC, axin, GSK-3, and CK-1α, leading to its degradation by the proteasome. TCF and Groucho bind to the
promoters of Wnt target genes and repress their expression. B) Upon binding of a Wnt ligand to the Frizzled receptor and LRP-5/6 co-receptor,
the destruction complex is disrupted by Dvl. In turn, β-cat enters the nucleus where it forms the bipartite transcription factor β-cat/TCF and
stimulates Wnt target gene expression. GPCR, G-protein coupled receptor. Dvl, dishevelled. APC, adenomatous polyposis coli. GSK-3, glycogen
synthase kinase-3. CK-1α, casein kinase 1α. IR, insulin receptor. HDAC, histone deacetylase. CtBP-1, C-terminal binding protein-1. H/N, hormone/
neurotransmitter. PKA, protein kinase A. Ins, insulin. CBP, cAMP response element-binding (CREB) binding protein.
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were able to stimulate insulin secretion in wild-type
but not LRP-5−/− mice [39]. Thus, Wnt-3a and
Wnt-5a rely on the function of LRP-5 to facilitate
insulin secretion.
Kanazawa and colleagues examined the association
between genes encoding members of the Wnt family
and T2D in a Japanese population [40]. They assessed
40 SNPs within 11 Wnt ligand genes, and showed that
six of them exhibited a significant difference in the al-
lele and/or genotype distributions between T2D and
control subjects. Among them, one SNP within Wnt-
5b was strongly associated with T2D. Wnt-5b appears
to be a repressive Wnt ligand with the ability to in-
hibit Wnt activity and promote adipogenesis [40,41].
In addition, Wnt-5b as well as Wnt-5a are involved in
coordinating chondrocyte proliferation and differenti-
ation [42]. Thus, the GWAS to date have revealed the
involvement of a Wnt ligand (Wnt-5b), Wnt co-
receptor (LRP-5) and the Wnt pathway effector
TCF7L2 (described further below) in the development
of diabetes.The role of the wnt signaling pathway in
adipogenesis and the function of adipocytes
The Wnt signaling pathway positively regulates bone
formation [25] and negatively regulates adipogenesis
[43]. Adipose tissue-specific over-expression of Wnt-10b
in mice led to ~50% lower adipose mass and the mice
were resistant to HFD-induced obesity [44]. Wnt-10b
null mice, on the other hand, exhibited increased adipo-
genic potential [45]. The repressive Wnt ligand Wnt-5b,
as mentioned above, was shown to promote adipogen-
esis [41].
In addition to the involvement of the Wnt signaling
pathway in adipogenesis, Wnt ligands produced by adi-
pocytes may function as paracrine or endocrine factors.
Adult adipocytes express different kinds of Wnt ligands.
Schinner and colleagues found that human fat-cell-
conditioned medium (FCCM) stimulates the prolifera-
tion of a pancreatic β-cell line and primary mouse islet
cells [46]. The FCCM was also shown to stimulate insu-
lin secretion from pancreatic β-cells, and the stimulation
can be blocked by the Wnt repressor, secreted frizzled-
related protein 1 (SFRP-1) [46]. However, it is not clear
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insulin secretion. Mechanisms underlying the stimula-
tion of hormone secretion are also elusive at this stage.Dispute on the function of wnt signaling pathway
in pancreatic islets
An early study by Murtaugh et al. suggests that although
β-cat is essential for pancreatic acinar cell development,
the loss of β-cat in a transgenic mouse model did not
significantly perturb islet endocrine cell mass or function
[47]. Papadopoulou and Edlund utilized the Pdx1-Cre
system to delete the β-cat gene in the epithelium of the
pancreas and duodenum only. They found that β-cat
mutant cells had a competitive disadvantage during de-
velopment. Although there was a reduction in the endo-
crine islet numbers during the developmental stages and
the mice had pancreatitis perinatally due to the disrup-
tion of the epithelial structure of acini, mice later recov-
ered from the pancreatitis and regenerated normal
pancreas and duodenal villi from the wild-type cells that
escaped the β-cat deletion [48]. Heiser et al., however,
found that induction of the expression of a stabilized
form of β-cat at different stages results in different
effects. During the early stage of organogenesis, robust
expression of stabilized β-cat (the S33Y mutant) pro-
voked changes in hedgehog and FGF-10 signaling and
induced the loss of expression of Pdx-1 [49], a homeo-
box gene that is important for the genesis of pancreatic
β-cells [50]. At a later time point in pancreas develop-
ment, S33Y mutant β-cat expression enhanced islet cell
proliferation and increased the size of pancreas [49]. The
seemingly contradictory results reported by the above
three groups can be resolved if we assume that β-cat
and the bipartite transcription factor β-cat/TCF exert
different functions in a precise dosage-dependent man-
ner at different developmental stages of the pancreatic
islets. Later, Rulifson et al. examined the effect of Wnt
signaling in regulating pancreatic β-cell genesis and pro-
liferation using both in vitro and in vivo approaches
[51]. They found that purified Wnt-3a stimulated β-cell
proliferation in both the mouse Min-6 cell line and pri-
mary mouse pancreatic islets, possibly through the cell
cycle regulators cyclin D1, cyclin D2 and CDK-4, as well
as the homeobox gene Pitx2. In the three month-old bi-
transgenic rat insulin promoter (RIP)-Cre and β-cat ac-
tive mice, immunohistological examinations revealed
increased levels of β-cat in both the cytoplasm and nu-
clei of pancreatic β-cells, along with a significant in-
crease in β-cell mass [51]. Their observations collectively
suggest that Wnt signaling is necessary and sufficient for
islet cell proliferation [51]. However, it is still not clear
how Wnt is mechanistically involved in the embryonic
genesis of pancreatic β-cells.TCF7L2 knockout mice were generated by Korinek and
colleagues in 1998 [12]. TCF7L2−/− mice die shortly after
birth, associated with the lack of proliferative compartments
in the prospective crypt regions between the intestinal villi
[12]. No examination was performed on potential abnormal-
ities in pancreatic development or metabolism in these
knockout mice during the neonatal stages. Two additional
TCF7L2 knockout mouse lines were generated recently by
separate groups [52,53]. The knockout mouse study by Savic
et al. indicated the potential deleterious effects of TCF7L2
on glucose metabolism [52]. Briefly, neonatal TCF7L2−/−
mice exhibited hypoglycemia, while TCF7L2+/− mice were
protected from diabetes [52].
Liu and Habener examined the role of Wnt signaling in
pancreatic β-cells from a different angle. They demon-
strated that both TCF7L2 and β-cat function as effectors
of the incretin hormone GLP-1 in stimulating β-cell pro-
liferation [54]. They also showed that mouse pancreatic
cells exhibit detectable Wnt activity, demonstrated in the
TOPGAL transgenic reporter mice [55]. Utilizing the
same β-cat/TCF-responsive TOPGAL mouse model,
Krutzfeldt and Stoffel, however, reported that Wnt signal-
ing is not appreciably active in the adult pancreas [56].
They suggest that abundant expression of the repressive
Wnt ligand Wnt-4 is at least partially responsible for the
lack of appreciable Wnt activity in the adult pancreas [56].
Together, although the Wnt signaling pathway is im-
portant for organogenesis, clarification of its role in pan-
creatic islet development requires further investigation.
More importantly, canonical Wnt signaling may not be
strong in the adult rodent pancreas. This notion is import-
ant for the exploration of the role of the T2D risk gene
TCF7L2 in mediating glucose homeostasis (see below).
TCF7L2 polymorphisms are associated with the
risk of T2D
GWAS have been making tremendous influences on
studies of diabetes and other genetic diseases [57-60].
During the last decade, extensive GWAS have shown
that 38 SNPs are associated with T2D and an additional
two dozen SNPs are associated with glycemic traits [59].
Among them, the T2D risk SNPs located in the TCF7L2
gene are the most exciting ones.
We have learned previously that a region on chromo-
some 10q is linked to T2D susceptibility [61,62]. In
2006, Grant et al. reported their major discovery on the
linkage between polymorphisms in TCF7L2 and the risk
of T2D [13]. Briefly, they revealed that certain SNPs
within intronic regions of TCF7L2 show robust associa-
tions with T2D [13]. This discovery has drawn global at-
tention and the findings have been replicated by
numerous groups among different ethnic populations
[14,17-19,22,23,58,60,63-76]. Figure 2A summarizes the
structure of the TCF7L2 gene and five SNPs that were
Figure 2 TCF7L2 genetic structure, T2D risk SNP locations, and protein structure. A) The human TCF7L2 gene, located on chromosome
10q25.3, consists of 17 exons (boxes). At least five exons are alternatively spliced (white boxes). Five SNPs were originally determined to be
associated with T2D risk in a variety of ethnic backgrounds, all of which are located within the large intronic regions surrounding exon 5. Two
additional T2D risk SNPs (yellow) were subsequently identified in Han Chinese populations. The TCF7L2 gene undergoes a significant amount of
alternative splicing that produces a large number of transcripts which give rise to a number of isoforms. The major isoforms of size 79 and
58 kDa result from alternative stop codons. A novel transcription start site (called Ex1b-e) was recently identified upstream of exon 6 which leads
to the production of a dominant-negative TCF7L2 isoform of size 35–40 kDa. B) The full-length TCF7L2 protein consists of two major domains
including the β-cat binding domain at the N-terminal as well as the HMG-box for binding to DNA. In addition, TCF7L2 binds to a number of
other factors, depicted in this figure. SNP, single nucleotide polymorphism. HMG, high-mobility group. HBP1, HMG-box transcription factor 1.
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and rs7903146 are the most strongly associated with
T2D, and subsequent reports determined that rs7903146
has the greatest effect in Caucasian populations.
Figure 2A also indicates two other SNPs which are asso-
ciated with T2D risk in Han Chinese by scientists in Tai-
wan and Hong Kong, respectively [64,75]. Furthermore,
an alternative promoter located upstream of exon 6,
named Ex1b-e and illustrated in Figure 2A, has recently
been discovered to generate a native dominant-negative
TCF7L2 protein in embryonic brain neurons [77].
Figure 2B depicts the protein structure of TCF7L2 which
consists importantly of an N-terminal β-cat binding do-
main that is lacking in dominant-negative TCF7L2.
Mechanistic exploration of the involvement of
TCF7L2 in glucose disposal
As the TCF7L2 T2D risk SNPs are located with intronic
regions, it is difficult to determine whether and how
these SNPs affect TCF7L2 expression level or its alterna-
tive splicing in a given tissue. Nevertheless, great effortshave been made by numerous groups to decipher the
potential role of TCF7L2 in pancreatic islets and other
tissues. Figure 3 summarizes the potential metabolic
functions of TCF7L2 we have learned to date.Controversial observations on the role of TCF7L2
in pancreatic β-cells
Initial investigations on the role of TCF7L2 in pancreatic
β-cells suggested potential deleterious effects of TCF7L2.
For example, Lyssenko et al. found that the CT/TT geno-
types of SNP rs7903146 are strongly associated with the
risk of T2D in two independent cohorts [23]. They
observed that the pancreatic islets in T2D patients showed
increased mRNA levels of TCF7L2. Furthermore, the T al-
lele carriers exhibited a significant elevation of TCF7L2
mRNA expression in their pancreatic islets, associated
with impaired insulin secretion and incretin effects [23].
As presented above, a more recent transgenic mouse
study also demonstrated a potential deleterious role of
TCF7L2 in mouse pancreatic islets [52].
Figure 3 Summary of the potential metabolic functions of TCF7L2. The beneficial versus deleterious role of TCF7L2 in the pancreas is
controversial and under debate. GLP-1, glucagon-like peptide-1. GIP, gastric inhibitory polypeptide.
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tiple lines of work by Shu and colleagues, which revealed
potential beneficial effects of TCF7L2 in pancreatic β-
cells [17,18]. They found that in isolated human or
mouse pancreatic islets, siRNA-mediated TCF7L2 deple-
tion resulted in a significant increase in β-cell apoptosis
and decrease in β-cell proliferation, associated with the
attenuation of glucose-stimulated insulin secretion [18].
In contrast, over-expression of TCF7L2 protected islets
from glucose- and cytokine-mediated apoptosis [18]. In
another study, while they showed increased TCF7L2
mRNA expression levels in the islets of various rodent
T2D models, they demonstrated that TCF7L2 protein
levels were actually decreased [17]. In parallel, expres-
sion of TCF7L2 as well as the GLP-1 receptor (GLP-1R)
and GIP receptor (GIPR) was also decreased in islets
from humans with T2D as well as in isolated human is-
lets depleted of TCF7L2 via siRNA treatment [17]. Fi-
nally, the stimulation of insulin secretion by glucose,
GLP-1 and GIP, but not KCl or cAMP, was impaired in
TCF7L2 siRNA-treated isolated human islets, while the
loss of TCF7L2 resulted in decreased GLP-1 and GIP-
stimulated AKT phosphorylation, and AKT-mediated
FOXO phosphorylation and nuclear exclusion [17].
These findings suggest that β-cell function and survival
are positively regulated by the expression of TCF7L2 in
T2D. The authors note that the earlier observations
showing increased TCF7L2 mRNA expression levels in
T2D may actually be consistent with their findings be-
cause protein levels of TCF7L2 are oppositely regulated.
Whether the expression of TCF7L2 protein is actually
decreased in T2D patients or carriers of risk SNPs has
not been reported.
The seemingly controversial conclusions made by dif-
ferent groups on the beneficial versus deleterious role of
TCF7L2 in pancreatic β-cells could also occur due to the
expression of different isoforms of TCF7L2 in a cell-typespecific manner [17,18,23,52,67]. A recent study demon-
strated that different isoforms of TCF7L2 in β-cells had
opposite effects on β-cell survival, function, and Wnt ac-
tivation [78], although no significant association has
been observed between T2D risk SNPs of TCF7L2 and
the alternative splicing of TCF7L2 [79]. Clearly, further
investigation is warranted to clarify the role of TCF7L2
in pancreatic islets.
The wnt signaling pathway and TCF7L2 regulate
the expression and function of the incretin
hormones
The role of TCF7L2 in hormone gene expression was
initially demonstrated by our group [80]. We found that
expression of the proglucagon gene (gcg) and produc-
tion of GLP-1 were stimulated in intestinal endocrine L
cells by lithium, which mimics the activation of Wnt sig-
naling by Wnt ligands. The positive regulation of gut
gcg expression by Wnt signaling was then confirmed
using a constitutively active β-cat mutant and dominant-
negative TCF7L2 [5,80,81], as well as the use of the Wnt
ligand Wnt-3a (unpublished data of Chiang and Jin).
Mechanistically, the activation is due to the binding of
β-cat/TCF7L2 to the G2 enhancer element of gcg pro-
moter, demonstrated by quantitative chromatin immu-
noprecipitation (ChIP) [5].
Another incretin hormone, GIP, is produced by intes-
tinal endocrine K cells [82]. The mouse small intestinal
cell line STC-1 expresses both GLP-1 and GIP. García-
Martínez demonstrated that both lithium and Wnt-3 not
only stimulate gcg expression, but also increase GIP
transcription in this cell line [83]. Lithium or Wnt-3 was
also shown to increase both cytoplasmic and nuclear
β-cat contents. Interestingly, they revealed via ChIP that
lithium treatment increased the occupancy of β-cat and
LEF-1 to the GIP gene promoter, associated with
reduced occupancy of TCF7L2 and the nuclear co-
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sence of Wnt signaling or lithium, GIP transcription is
repressed through the occupancy of the GIP promoter
by TCF7L2 and HDAC1. In response to increased β-cat,
the β-cat/LEF-1 complex replaces the TCF7L2/HDAC
complex, thus leading to the stimulation of GIP tran-
scription and GIP production. Although this notion
requires further examination, we can conclude that Wnt
signaling and its effectors β-cat and TCF proteins are
involved in the production of both GLP-1 and GIP, two
known incretin hormones.
Pancreatic β-cells are the most important targets of
GLP-1 and GIP. GLP-1 and its long-acting analogue
exendin-4 (Ex-4) not only stimulate insulin secretion by
β-cells, but also up-regulate pro-insulin gene expression,
activate β-cell proliferation, and protect β-cell from
stress induced apoptosis. Liu and Habener found that
Ex-4 induces Wnt signaling in pancreatic β-cells [54].
They found that the expression of two known Wnt
downstream targets, cyclin D1 and c-Myc, which are es-
sentially involved in β-cell proliferation, can be stimu-
lated by Ex-4. Furthermore, they showed that β-cat
Ser675 phosphorylation is stimulated by Ex-4 treatment
in the Ins-1 cell line. Finally, they demonstrated the es-
sential role of TCF7L2 in both basal and Ex-4-
stimulated β-cell proliferation utilizing both an siRNA
approach and the TCF7L2 dominant-negative molecule
[54]. Thus, Wnt signaling and its effectors β-cat and
TCF proteins are important for both the production and
function of the incretin hormone GLP-1 [5,84,85]. As
presented above, Shu et al. established the positive rela-
tionship between the level of TCF7L2 and the levels of
incretin receptors, including GLP-1R and GIPR [17].
Thus, the function of GIP is also indirectly regulated by
TCF7L2, although more detailed mechanisms need to be
explored.
TCF7L2 and the wnt signaling pathway regulate
hepatic gluconeogenesis
TCF7L2 is expressed in organs other than the gut and
pancreatic islets, including liver, brain, muscle and fat
tissues. As these organs are involved in mediating meta-
bolic homeostasis as well, it is necessary and interesting
to examine the metabolic function of TCF7L2 and Wnt
signaling in those organs.
Lyssenko et al. found that the CT/TT genotypes of
SNP rs7903146 were also associated with enhanced rates
of hepatic glucose production [23]. A subsequent human
study also demonstrated that this risk allele was asso-
ciated with elevated hepatic glucose production, even in
patients undergoing a hyperinsulinemic clamp [76].
The Wnt signaling pathway is known to be important in
the development and zonation of the embryonic liver [86].
However, little effort has been made to explore the hepaticrole of TCF7L2 and Wnt signaling in regulating glucose
homeostasis in adulthood until very recently. Liu et al.
found that starvation induced the expression of mRNAs
that encode different Wnt isoforms in hepatocytes. They
also demonstrated using loss- and gain-of-function mod-
els that β-cat is a positive regulator of hepatic glucose pro-
duction [87]. Briefly, β-cat ablation improved glucose
disposal and reduced the expression of the rate-limiting
gluconeogenic genes, including phosphoenolpyruvate car-
boxykinase (PEPCK) and glucose-6-phosphatase (G6Pase).
Over-expression of β-cat, however, produced reciprocal
effects on hepatic gluconeogenesis [87]. Norton and col-
leagues, however, demonstrated that TCF7L2 silencing led
to increased basal levels of hepatic glucose production in
a rat hepatic cell line, associated with the over-expression
of gluconeogenic genes [88]. Thus, TCF7L2 is a potential
negative regulator of gluconeogenesis. Indeed, we found
that the Wnt ligand Wnt-3a repressed glucose production
in primary hepatocytes and cultured hepatic cell lines (un-
published data of Ip and Jin). These seemingly contradict-
ory observations between the roles of β-cat and TCF7L2
can be resolved by considering the crosstalk among Wnt,
metabolic insulin and the aging/stress FOXO signaling
pathways (discussed further below).Potential metabolic effect of TCF7L2 in other
organs
Wnt signaling negatively regulates adipogenesis [43] and
positively regulates bone formation [25]. Furthermore,
Wnt ligands released by adipocytes stimulate insulin se-
cretion [46]. TCF7L2 is expressed in adipocytes and its
expression can be down-regulated by insulin [89]. In
vitro assays showed that insulin repressed TCF7L2
mRNA expression, and the repression can be attenuated
by insulin resistance with the addition of free fatty acids
palmitate or oleate. Insulin resistant human subjects ex-
press higher levels of TCF7L2 in subcutaneous adipose
tissue [89]. Prokunina-Olsson and colleagues demon-
strated that omental and subcutaneous adipose tissue
express different alternatively spliced forms of TCF7L2.
However, there is no association between the expression
of alternatively spliced TCF7L2 isoforms and TCF7L2
T2D risk SNPs [16]. TCF7L2 is also expressed in skeletal
muscle, although its role in glucose uptake or insulin
signaling is currently unknown [79].
TCF7L2 is expressed in the brainstem, hypothalamus,
and other areas of the brain. TCF7L2 knockout mice
show abnormalities in their pituitary gland [90]. Since
both incretin hormones and their receptors are
expressed in brain neurons [91], and brain GLP-1 signal-
ing controls satiety and peripheral insulin signaling
[91,92], it is important to examine whether brain
TCF7L2 play a role in energy and glucose homeostasis.
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FOXO proteins mediate the effects of stress and aging.
The functions of FOXO proteins are negatively regulated
by insulin and certain growth factors [93]. In the absence
of insulin or growth factors, FOXOs are mainly located
within the nuclei and up-regulate a set of target genes
that promote cell cycle arrest, stress resistance, as well
as apoptosis [94]. Insulin and a battery of growth factors
may activate PKB or serum- and glucocorticoid-
regulated protein kinase (SGK), resulting in the stimula-
tion of FOXO phosphorylation and nuclear exclusion
[93]. Essers et al. demonstrated an evolutionarily con-
served interaction between FOXOs and β-cat, suggesting
the existence of crosstalk between FOXO and Wnt sig-
naling pathways [95]. Since FOXO can be inactivated by
insulin and growth factors, scientists have explored the
relationship among these three essential signaling cas-
cades. Indeed, extensive investigations have revealed that
oxidative stress plays a pathogenic role in skeletal invo-
lution, independent of aging [25,26,96-99]. More import-
antly, recent studies have further demonstrated a novel
pathophysiological role for the interaction between
FOXO proteins and β-cat in bone diseases: the reductionFigure 4 Crosstalk among Wnt, insulin, and FOXO signaling cascades
β-cat. Aging and oxidative stress shift the balance in favor of FOXO signalin
insulin and growth factors shift the balance in favor of Wnt/TCF signaling b
activating β-cat, thus resulting in the activation of downstream Wnt target
N-terminal kinase. FOXO, forkhead box O. SGK, serum and glucocorticoid kof β-cat/TCF-mediated gene expression. Figure 4 illus-
trates our current understanding of the crosstalk be-
tween the three signaling cascades. Obviously, β-cat is
“not just for frizzleds anymore” [100]. The function of β-
cat is bi-directional. This pivotal molecule regulates
many physiological and pathological events via control-
ling cell cycle progression and cell growth. When
teamed up with TCF, β-cat activates Wnt target gene ex-
pression and stimulates these two processes. When it is
partnered with FOXOs, β-cat stimulates FOXO target
gene expression and represses cell cycle progression and
cell growth. Hence, FOXOs and TCF factors compete
for a limited pool of β-cat, such that the balance is
shifted towards FOXO activity during aging and oxida-
tive stress. Insulin and growth factors, however, are able
to restore balance [27].
As presented above, TCF7L2 and Wnt signaling are
likely negative regulators of hepatic gluconeogenesis
[88]. However, β-cat ablation improves glucose disposal
and inhibit gluconeogenic gene expression [87]. How
can one explain the opposite outcomes of knocking-
down these two effectors of the Wnt signaling pathway
on hepatic gluconeogenesis? We suggest that this
involves the crosstalk among the three signaling. TCF and FOXO compete with each other for a limited pool of free
g via JNK to activate downstream FOXO target genes. Contrastingly,
y facilitating the nuclear exclusion of FOXO via PKB/SGK as well as by
genes. PKB, protein kinase B. ROS, reactive oxygen species. JNK, c-Jun
inase.
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factor for FOXOs in up-regulating gluconeogenic gene
expression during fasting in response to the elevation of
glucagon levels. Glucagon signaling results in the up-
regulation of FOXO-mediated gene transcription to
stimulate gluconeogenesis. However, upon feeding, insu-
lin inhibits FOXO. We speculate that this will then allow
free β-cat to bind to TCF7L2 and contribute to the re-
pression of gluconeogenic gene expression. In the case
of Wnt activation or TCF7L2 over-expression, FOXOs
may be outcompeted by excess TCF7L2 and/or β-cat
may no longer be a limiting factor. This speculation is
supported by our observation that Wnt-3a represses glu-
cose production and that insulin is able to stimulate β-
cat Ser675 phosphorylation in hepatocytes (unpublished
data of Ip and Jin). Alternatively, TCF7L2 may utilize a
yet to be explored mechanism or co-factor to exert its
repressive effect on gluconeogenic gene expression.
Summary and perspective
Extensive investigations have shown that the Wnt signal-
ing pathway controls hormone gene expression and
mediates the function of certain hormones including
GLP-1, GIP and insulin, which are critically important in
glucose and energy homeostasis. We have also learned
from GWAS that polymorphisms in certain Wnt ligands
(such as Wnt-5b), the Wnt co-receptor LRP-5/6, as well
as the Wnt effector TCF7L2, are strongly linked with
T2D risk. We anticipate that further mechanistic explor-
ation of the underlying mechanisms for these linkages
will lead to the discovery of novel therapeutic targets of
T2D and other metabolic disorders.
T2D is a chronic and age-dependent disorder. A fun-
damentally important advancement in the basic research
of the Wnt signaling pathway is that β-cat/TCF mediates
not only the effect of Wnt ligands, but also other cell
signaling molecules during adulthood, including insulin,
IGF-1, as well as peptide hormones/neurotransmitters
that utilize cAMP as a second messenger [27]. These
findings have not only enriched our knowledge of the
function of peptide hormones/neurotransmitters, but
also deepened our understanding of the existence of
crosstalk among the stress/FOXO, developmental/Wnt,
and metabolic/insulin signaling cascades, as presented in
Figure 4. Nuclear FOXO levels rise during aging as a re-
sult of the accumulation of reactive oxygen species and
JNK signaling activation. FOXOs are able to compete
with TCF for a limited pool of β-cat. This leads to
reduced Wnt activity, which is important for glucose
and lipid metabolism. On the other hand, insulin and
growth factors are able to inactivate FOXOs and hence
restore the balance. The establishment of this concept
creates a new perspective on the pathophysiology of
T2D and other age-dependent disorders.It is clear that TCF7L2 polymorphisms are strongly
associated with the risk of T2D in different ethnic popu-
lations. Molecular mechanisms underlying this associ-
ation, however, are far from understood at this time. No
risk SNPs of T2D are located within the coding region
of TCF7L2, or a region that can be reliably determined
to have an effect on its expression or alternative splicing.
In the near future, we anticipate more thorough investi-
gations on the association between TCF7L2 SNPs and
its alternative splicing in pancreatic islets and extra-
pancreatic organs. Great insights can also be acquired
through further exploration of the beneficial versus dele-
terious effects of TCF7L2 alternatively spliced variants in
different organs.
In summary, the recognition of the involvement of
Wnt components in metabolic homeostasis and the as-
sociation between TCF7L2 polymorphisms and the risk
of T2D have further prompted investigations into the
role of Wnt signaling in the production and function of
the incretin and other peptide hormones, as well as glu-
cose disposal and insulin signaling. Although the major-
ity of studies have been conducted in pancreatic β-cells,
we anticipate further examinations on the role of Wnt
signaling and its effectors in extra-pancreatic organs.
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